高级检索
当前位置: 首页 > 详情页

Evaluation of Bleeding Risk of Cataract Phacoemulsification in Patients with Long-term Aspirin Use after Percutaneous Coronary Intervention

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ ESCI

机构: [1]Capital Med Univ, Beijing Anzhen Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China [2]China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China
出处:
ISSN:

关键词: Aspirin bleeding risk percutaneous coronary intervention phacoemulsification

摘要:
PURPOSE: It is a controversial issue whether to discontinue antithrombotic drugs during the perioperative period of cataract surgery. There are few reports on the safety of long-term aspirin use after percutaneous coronary intervention (PCI). In this study, we evaluated the bleeding risk and surgical safety of cataract phacoemulsification in patients who took aspirin for a long time after PCI, so as to provide relevant evidence for this problem. METHODS: Retrospective analysis of the cases of cataract surgery. The incidence of bleeding-related complications in patients without history of antithrombotic drugs, patients without cardiac surgery who had taken aspirin at least 1 year for secondary prevention, and patients with long-term aspirin use 1 year after PCI were compared. RESULTS: A total of 81 patients (81 eyes, n = 81) after PCI (>= 1 year) were collected. One hundred fifty-eight patients (158 eyes, n = 158) without cardiac surgery in the aspirin group and 285 patients (285 eyes, n = 285) without history of antithrombotic drugs were collected. Subconjunctival hemorrhage and hyphema occurred in all three groups, but the difference was not statistically significant (P > 0.05). No other serious bleeding-related complications occurred in the three groups during the operation, 1 day and 1 week after operation. CONCLUSION: No matter intraoperative or postoperative, bleeding-related complications are rare in patients after PCI, which demonstrates a certain degree of surgical safety and can prove the safety of cataract surgery without stopping antithrombotic drugs.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 眼科学
JCR分区:
出版当年[2021]版:
最新[2023]版:
Q4 OPHTHALMOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Anzhen Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23549 今日访问量:0 总访问量:1282 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)